EUVIMEDEUVIMED entdecken
Crossref

Discovery of C2: A Novel Lead Compound for the Treatment of Gout and Hyperuricemia via Multi‐Pathway Inhibition

Lina Jing, Ruoyang Miao, Chunli Zhang, Chunxia Liu iD

Archiv der Pharmazie · 2026-04 · 359 (4)

DOI: 10.1002/ardp.70234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 08.04.2026. Verfasst von Lina Jing und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comprehensive Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengz…. Hauptthemen laut MEDLINE: Hyperuricemia, Gout, Drug Discovery, Gout Suppressants. Die Arbeit nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Health Commission of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout and hyperuricemia, prevalent metabolic disorders, are driven by elevated serum uric acid (UA) levels and subsequent monosodium urate crystal deposition, which provoke inflammatory responses and joint damage. Current therapeutic options remain unsatisfactory, underscoring the urgent need for novel agents with improved efficacy and safety profiles. In this study, we aimed to discover a new lead compound capable of concurrently addressing both hyperuricemia and associated inflammatory pain. Two novel compounds were designed and synthesized, among which C2 was identified as a promising candidate. In vitro, C2 exhibited potent dual inhibitory activity against transient receptor potential vanilloid 1 (TRPV1)—a key mediator of inflammatory pain signaling—and urate transporter 1 (URAT1), which regulated renal UA reabsorption, with IC₅₀ values of 78.52 ± 14.50 nM and 598.6 ± 115.5 nM, respectively. In vivo, oral administration of C2 (20 mg/kg) significantly reduced serum UA levels in a hyperuricemic mouse model, demonstrating efficacy comparable to dotinurad. Furthermore, in a formalin‐induced inflammatory pain model, C2 produced dose‐dependent antinociceptive effects. Mechanistic investigations revealed that C2 suppressed NLRP3 inflammasome activation in THP‐1 cells, as indicated by reduced IL‐1β secretion. Additionally, C2 ameliorated dextran sulfate sodium‐induced colitis in mice, accompanied by improved histopathological scores. Collectively, these results establish C2 as a multi‐target lead compound that acts simultaneously on UA transport, nociceptive signaling, and the NLRP3 inflammasome pathway, providing a strong rationale for its further development as a novel therapeutic strategy for gout and hyperuricemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaGoutDrug DiscoveryGout SuppressantsAnalgesicsAnimalsHumansMiceMaleStructure-Activity RelationshipDose-Response Relationship, DrugUric AcidDisease Models, AnimalTRPV Cation ChannelsMolecular StructurePainMice, Inbred C57BLSignal TransductionAdministration, OralOrganic Anion Transporters

Stichwörter der Autor:innen

NLRP3TRPV1URAT1analgesicgout

Substanzen

Uric AcidGout SuppressantsAnalgesicsTRPV Cation ChannelsOrganic Anion Transporters

Autor:innen und Institutionen

  • Department of Comprehensive Surgery, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, People's Republic of China.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
  • Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, People's Republic of China.

ORCID-Profile: Chunxia Liu

Förderung

  • National Natural Science Foundation of China
  • Health Commission of Henan Province

Zitieren

APA

Jing, L., Miao, R., Zhang, C., & Liu, C. (2026). Discovery of C2: A Novel Lead Compound for the Treatment of Gout and Hyperuricemia via Multi‐Pathway Inhibition. Archiv der Pharmazie, 359(4). https://doi.org/10.1002/ardp.70234

Vancouver

Jing L, Miao R, Zhang C, Liu C. Discovery of C2: A Novel Lead Compound for the Treatment of Gout and Hyperuricemia via Multi‐Pathway Inhibition. Archiv der Pharmazie. 2026;359(4). doi:10.1002/ardp.70234

BibTeX
@article{Jing2026,
  author = {Jing, Lina and Miao, Ruoyang and Zhang, Chunli and Liu, Chunxia},
  title = {Discovery of C2: A Novel Lead Compound for the Treatment of Gout and Hyperuricemia via Multi‐Pathway Inhibition},
  journal = {Archiv der Pharmazie},
  year = {2026},
  volume = {359},
  number = {4},
  doi = {10.1002/ardp.70234}
}
Kostenlos starten →